.png?width=150&name=MMS%20logo_without%20Tagline%20(Full%20Color).png "MMS logo_without Tagline (Full Color)")
Together Trial with EDC Database Designed by MMS Wins Trial of the Year
CANTON, Mich. (8/16/2022) – The TOGETHER Trial, which uses an Electronic Data Capture (EDC) system designed, ...
Clinical Trial Disclosures 101: The Basics You Need to Know
As regulations around clinical trial data disclosure continue to increase in complexity, it can be difficult ...
MMS Holdings Partners with Lindsay Goldberg for Its Next Stage of Growth
The partnership will help MMS expand its award-winning services to pharma and biotech companies and extend ...
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration Between MAPS PBC and MMS Holdings
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy ...
Attending the American Chemical Society Central Regional Meeting 2022 – Key Highlights
By: Jessica Reed, Ph.D., Associate Director, Project Advisory Services
Medical Writing Trends in the Era of COVID-19 and Remote Work: Enhancing Virtual Relationships and Emphasizing Emotional Intelligence
By: Ananya Bhowmick, Ph.D., Medical Writer
MMS Holdings Announces Partnership with Medidata to Provide Medidata’s Advanced Rave EDC and Decentralized Clinical Trial Solutions to Sponsors
CANTON, MI (6/7/2022) – MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to ...
Attending the 2022 PHUSE US Connect: A Data Scientist’s Experience
By: Chris Hurley, Director of Data Science
MMS Holdings Selects THREAD as Partner of Choice to Deliver Decentralized Clinical Trials
CANTON, Mich. (05/24/2022) – MMS Holdings Inc. (MMS) – an award-winning, data-focused contract research ...
A Message from our Founder on International Clinical Trials Day
At MMS, we take great pride in our work as a data CRO and hence May 20th has a special significance for us as ...
Key Takeaways from FDA GCP Inspection Trends in 2021
By: Melissa Sullivan, Senior Quality and Compliance Specialist
Forever Chasing the Shiny New Thing: Thoughts from a Long-time Biostatistician
By: Kevin Chartier, Ph.D., Principal Advisor, Biostatistics and Submissions Planning